FINAL REPORT OF THE
5TH MEETING OF THE DOTS EXPANSION WORKING GROUP

27–28 October 2004
Paris, France

World Health Organization
Geneva
FINAL REPORT OF THE 5TH MEETING OF THE DOTS EXPANSION WORKING GROUP

27–28 October 2004
Paris, France

World Health Organization
Geneva
Acknowledgements

This report was prepared by Amy Piatek, with assistance from Malgosia Grzemska and Léopold Blanc. Thanks are due to all the members of the DOTS Expansion Working Group (DEWG) and other participants in the meeting.

The meeting was organized in collaboration with the KNCV Tuberculosis Foundation and funded in part by the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, United States Agency for International Development (USAID), the International Union Against Tuberculosis and Lung Disease (IUATLD), a grant from the World Bank’s Development Grant Facility to the Stop TB Partnership and the World Health Organization (WHO).
Contents

1. Introduction ................................................................................................................ .............. 1
2. Report of the DEWG Secretariat ............................................................................................. 1
  2.1 Status of DOTS expansion in HBCs ..................................................................................... 1
  2.2 Epidemiological update ......................................................................................................... 2
  2.3 Financial situation ................................................................................................................. 3
    2.3.1 Expenditures and funding gaps ...................................................................................... 3
    2.3.2 Resource mobilization .................................................................................................... 3
  2.4 Intensified support and action countries (ISAC) ................................................................. 4
  2.5 DEWG subgroups ................................................................................................................. 4
    2.5.1 Childhood TB .................................................................................................................. 4
    2.5.2 Laboratory capacity strengthening ................................................................................. 5
    2.5.3 Public-private Mix (PPM) DOTS ..................................................................................... 5
3. Evolution of DOTS ........................................................................................................... ........ 6
  3.1 TB care for all: evolution of the DOTS strategy ................................................................. 6
  3.2 Developing an international standard for TB care ............................................................ 6
  3.3 The second Global Plan to Stop TB (2006–2015) ........................................................... 7
4. Laboratory services in the 22 high burden countries ............................................................... 7
  4.1 Laboratory Issues: proposed action by the DEWG ............................................................ 7
5. Key issues in DOTS implementation ....................................................................................... 8
  5.1 Human resources: the role of nurses .................................................................................... 8
  5.2 Collaboration with other health-care providers ................................................................. 8
    5.2.1 Scaling-up PPM-DOTS in India ..................................................................................... 8
    5.2.2 Business sector contributions to the global effort to Stop TB ........................................ 9
    5.2.3 Strengthening TB control through social franchising: experiences from Myanmar ....... 9
    5.2.4 National partnership: Uganda ...................................................................................... 10
  5.3 Important issues for DOTS expansion ............................................................................... 10
    5.3.1 TB and poverty ........................................................................................................... .. 10
    5.3.2 TB Diagnostic Kits Initiative .......................................................................................... 10
    5.3.3 Tuberculosis and HIV – future directions ..................................................................... 10
  5.4 Integrating DOTS-Plus components into DOTS programmes ............................................ 11
6. Conclusions ......................................................................................................................... 12
7. Next meeting ....................................................................................................................... 13

Annex 1. Laboratory services in the 22 HBCs .............................................................................. 15
Annex 2. Agenda ........................................................................................................................... 19
Annex 3. List of participants ...................................................................................................... 21
Abbreviations and acronyms

AFB  Acid fast bacilli
ART  Antiretroviral therapy
ATS  American Thoracic Society
CDC  Centers for Disease Control and Prevention, USA
CIDA Canadian International Development Agency
COMBI Communication for behaviour impact
DEWG DOTS Expansion Working Group
DFID Department for International Development, United Kingdom
DOTS The internationally recommended strategy for TB control
DRS  Drug resistance surveillance
DST  Drug susceptibility testing
EQA  External quality assurance
FDC  Fixed-dose combination
FIDELIS Fund for Innovative DOTS Expansion through Local Initiatives to Stop TB
GDF  Global Drug Facility
GFATM Global Fund to Fight AIDS, Tuberculosis and Malaria
GLC  Green Light Committee
HBC  High burden country
HIV  Human immunodeficiency virus
HR  Human resources
HRD  Human resources development
IEC  Information, education, and communication
ISAC  Intensified support and action countries
IUATLD International Union Against Tuberculosis and Lung Disease
KNCV Royal Netherlands Tuberculosis Association
MDG  Millennium Development Goal
MDR  Multidrug resistant
MSF  Médecins Sans Frontières
MSH  Management Sciences for Health
NGO  Nongovernmental organization
NRL  National reference laboratory
NTP  National tuberculosis programme
PPM  Public-Private Mix
PSI  Population Services International, Myanmar
QA  Quality assurance
SCC  Short course chemotherapy
SQH  Sun Quality Health franchise, Myanmar
TB  Tuberculosis
TBCTA  Tuberculosis Coalition for Technical Assistance
UNAIDS Joint United Nations Programme on HIV/AIDS
USAID United States Agency for International Development
WEF  World Economic Forum
WHA  World Health Assembly
WHO  World Health Organization
ZN  Ziehl-Neelsen (stain)
1. Introduction

The fifth meeting of the DOTS Expansion Working Group (DEWG) was held on 27 and 28 October 2004 in Paris, France in conjunction with the 35th International Union Against Tuberculosis and Lung Disease (IUATLD) World Conference on Lung Health. The first day of the meeting was closed, to include only the representatives of the 22 high burden countries (HBCs) for tuberculosis (TB), financial and technical partners, and regional and country offices of the World Health Organization (WHO).

The second day of the meeting – which was hosted by the IUATLD – was open to all participants of the IUATLD conference. The final agenda of the meeting, and the complete list of participants are included as annexes to this report. The meeting was financially supported in part by the Global Bureau for Population, Health and Nutrition of the United States Agency for International Development (USAID); IUATLD; the World Bank; and WHO.

The objectives of the meeting were to:

- review the status of TB control and DOTS expansion in the world;
- identify and discuss constraints of the 22 HBCs in achieving the 2005 targets and the Millennium Development Goals (MDGs), and discuss solutions and activities to be implemented in 2005 – the last year for corrective and innovative actions for achieving the global TB targets;
- review the national laboratory systems and networks and develop a plan to strengthen laboratories;
- discuss collaboration with other health-care providers, including public-private mix, public-public mix, TB control in the workplace, and community TB; and
- present and discuss the intensified support and action countries (ISAC) initiative.

The expected outcome was an up-to-date plan to support country activities for DOTS expansion, outlining action needed by countries and their international partners to reach the 2005 targets.

2. Report of the DEWG Secretariat

2.1 Status of DOTS expansion in HBCs

Information on DOTS expansion, progress, and activities between 1 July 2003 and 30 June 2004 was collected from the 22 HBCs, based on a questionnaire developed by the WHO Stop TB Department. Many countries reported rapid expansion of DOTS in various aspects of their health systems during the past year. India has expanded DOTS coverage to an additional 179 million people (approximate 76% total population coverage) and has an approved national plan for 100% DOTS coverage by 2005.

Moreover, a major scaling-up of Public-Private Mix (PPM) DOTS – and involvement of medical colleges and health facilities under other than governmental ministries – has taken place over the past year. Myanmar achieved 100% DOTS coverage in December 2003, and has reached the global targets for case detection at 73%. The Government of China has pledged to greatly increase funding for TB control and continued DOTS expansion. In the African region, Nigeria has further expanded DOTS and Uganda has expanded community-based DOTS. The Russian Federation has gradually expanded DOTS in accordance with its five-year plan, and has implemented a new recording and reporting system based on a WHO cohort analysis. In that country, the World Bank loan and the Global Fund to Fight AIDS, TB and Malaria (GFATM) grant for TB have been approved and will significantly impact DOTS expansion and TB control activities. South Africa has also implemented a uniform cohort-based recording and reporting system in all provinces. Pakistan has
had rapid expansion of DOTS, including PPM DOTS, through the nongovernmental organization (NGO) network. Viet Nam has expanded DOTS to cover remote areas, the Philippines has further expanded DOTS into the private sector and hospitals, and Cambodia has doubled the number of health centres providing DOTS in 2003 and has introduced community DOTS in collaboration with NGOs in remote areas. The Philippines has also developed guidelines on childhood TB.

The National TB Control Plan for 2004–2007 to expand DOTS was approved in Brazil. Bangladesh achieved 84% treatment success, and the National Tuberculosis Programme (NTP) has strengthened its collaboration with numerous NGOs that provide DOTS services countrywide. Greater involvement of other public health providers in DOTS as part of public-public DOTS, and improved supervision and monitoring, are adding to the success of TB control in Indonesia. Kenya has expanded PPM DOTS, and developed and implemented a communication for behaviour impact (COMBI) plan to improve early case detection. Both Pakistan and Uganda have launched Stop TB Partnerships, and in Pakistan this launch has resulted in increased funding from the government for further TB control activities.

There have been positive changes in the national TB programmes of several countries. The organizational structure of the NTP in Afghanistan at the national, provincial, and district levels was formulated, and NTP guidelines and other materials have been developed. There has been a major strengthening of NTP capacity in Indonesia at both central and provincial levels, and the national TB laboratory has been reinstated in Kenya. In Viet Nam, both a nationwide external quality assurance (EQA) system and a mechanism to ensure quality of anti-TB drugs was established.

Development of human resources (HR) was a main activity for many HBCs during the year. Major plans to strengthen HR were developed in China and India. Training activities and capacity building were significant activities in Ethiopia, Indonesia, Nigeria, the Russian Federation, South Africa, and the United Republic of Tanzania. TB/HIV collaborative activities have begun in some areas. In Kenya, a TB/HIV working group and guidelines were established. A TB/HIV coordinator was appointed and collaborative activities were launched in Mozambique. In South Africa, national guidelines for the care of co-infected TB patients were developed, which include access to antiretroviral therapy (ART).

2.2 Epidemiological update

Preliminary data suggest that by the end of 2003, 77% of the world's population lived in countries – or parts of countries – covered by DOTS: an increase from 69% in 2002. In 2002, 180 countries were implementing DOTS. Among those countries (170 out of 210) who had reported to the World Health Organization by 12 October, two new countries had adopted the DOTS strategy in 2003.

Many countries have made progress towards achieving the 2005 global TB targets of 70% case detection and 85% treatment success. The global case-detection rate continues to accelerate: preliminary figures suggest a rate of 43% for 2003 (37% in 2002). The treatment success rate for patients registered in 2002 is close to the target, at 82%. However, treatment success is below average in Africa (71%) and in eastern Europe (70%). The case-detection rate for 2003 was above 70% in only three HBCs (Myanmar, South Africa, and Viet Nam). Only in Viet Nam have both targets (70% case detection and 85% treatment success) been achieved. Two HBCs with high HIV prevalence – Kenya and the United Republic of Tanzania – have reported treatment success rates above 80%. Myanmar and the Philippines are also close to the targets.

WHO is now routinely reporting on progress towards the MDGs for 2015 (halving TB prevalence and deaths), as well the global TB targets for 2005 (70% case detection and 85% treatment success). WHO is continuing to carry out a series of case studies to evaluate the impact of TB control on incidence, prevalence, and deaths. These case studies are identifying a wide range of approaches to improving case detection. Through a series of regional workshops, WHO has
provided countries and partners with guidance on best practices and tools for analysing routine and survey data and using results to form policy.

2.3 Financial situation

2.3.1 Expenditures and funding gaps

Expenditure on TB control in the HBCs in 2002 was US$ 834–884 million. This was lower than the anticipated expenditure of US$ 976 million, the sum that would have been required – in WHO's estimation – to achieve 70% case detection by 2005. Estimated expenditures for the HBCs in 2003 totalled approximately US$ 1 billion. This figure reflects an increase of about US$ 150 million from 2002 expenditures, but is probably still too low to meet the target for case detection by 2005.

In 2003, the governments of HBCs contributed (from national funds and loans) 70% of funds specified in NTP budgets, and 87% of total costs. But government contributions to total costs varied from 0% (Afghanistan) to 100% (e.g. Brazil), and tended to be greater in richer countries. External grants contributed about one half or more of the NTP budgets of Afghanistan, Bangladesh, the Democratic Republic of the Congo, Ethiopia, Pakistan, and the United Republic of Tanzania.

The overall funding gap reported by HBCs (excluding South Africa and Zimbabwe, for which there were no data) was US$ 41 million in 2003, about 4% of total costs, but a much larger fraction of the costs in poorer countries. Between 2002 and 2003, the funding gap narrowed in seven countries, mainly because more funds were promised by governments (including loans) and the GFATM. The gap increased in five countries because more (unfunded) activities were planned to accelerate DOTS expansion.

WHO estimated that, if the 2005 targets for case detection and treatment success are to be met, US$ 0.95 billion must be spent in the HBCs (except the Russian Federation) in 2004, and US$ 1.1 billion in 2005, compared with US$ 0.65 billion spent in 2002 and US$ 0.85 billion budgeted for 2003. The Russian Federation reported a budget of around US$ 400 million for 2004, of which US$ 200 million is yet to be found.

2.3.2 Resource mobilization

Funding for DOTS expansion activities is being mobilized through links with bilateral financial partners from the Canadian International Development Agency (CIDA), Italy, Japan, and USAID, among others. DOTS expansion should also be linked with the GFATM to coordinate support through technical partners, to provide in-country support to prepare proposals, and to stimulate applications in countries with large funding gaps. All except three of the HBCs have received TB funding from the GFATM. The Fund for Innovative DOTS Expansion through Local Initiatives to Stop TB (FIDELIS) is also supporting new approaches to increase case detection.

• The GFATM will make a major contribution to TB control in some countries, provided that the money can be disbursed and absorbed quickly. By the end of 2003, the GFATM had approved grants (for up to 5 years) of US$ 608 million for TB control activities, and US$ 319 million for TB/HIV control, in 56 countries. The total contribution for the first two years was US$ 294 million for TB control and US$ 90 million for TB/HIV, but only 16% had been disbursed by the end of 2003. The launching of the fifth round of proposals is planned for mid-2005. To better support countries that intend to apply for grants in the upcoming round, a workshop was held in Geneva during the first quarter of 2005. The purpose of this workshop was to instruct country experts and consultants from the partner organizations in the elements of a well-prepared proposal and to provide recommendations on the essential technical areas to be included in those proposals.
• FIDELIS is a new funding mechanism, initiated by CIDA in 2003 and managed by IUATLD. Specifically, FIDELIS aims to cure new sputum-positive cases, prioritizing those with limited access to health services. This mechanism provides support to countries for implementing innovative approaches to TB control, focusing on improving case detection – especially among hard-to-reach populations. At the time of the presentation of this Report of the DEWG Secretariat, 16 projects were being implemented and an additional 16 approved projects were likely to start implementation by October 2004. Innovations in these projects included decentralizing existing services, improving referrals, promoting community-based DOTS, intensifying information, education, and communication (IEC), involving private health-care providers, encouraging joint ventures between national tuberculosis programmes (NTPs) and NGOs, and providing for the payment of performance-based incentives to peripheral health-care workers.

2.4 Intensified support and action countries (ISAC)

ISAC is a special emergency Stop TB initiative – implemented through the DEWG – to accelerate DOTS expansion and reach the 2005 targets within the Global Plan to Stop TB, and ultimately the 2015 Millennium Development Goals (MDGs). ISAC is an extraordinary and additional effort to accelerate TB control – regular efforts by the DEWG continue to support all 22 HBCs and other countries in need.

Countries were selected based on the following criteria:
- burden of disease and/or of TB/HIV dual infection;
- presence of – or desire to have – in-country WHO or Stop TB partners' staff and intensified support;
- clear commitment and potential capacity to implement the programme at the country level and provide an enabling environment;
- availability of funding for TB or TB/HIV control activities from GFATM, bilateral donors, and/or banks; and
- the potential for collaboration with the Global Drug Facility (GDF) for drug procurement.

The first tier of ISAC countries includes China, India, Indonesia, Kenya, Pakistan, Peru, Romania, the Russian Federation, and Uganda, (although the plan for Peru is not yet available). The main ISAC donors to date are CIDA, the Department for International Development, United Kingdom (DFID), GFATM, USAID, and the governments of Italy, Japan, and Norway. The next steps anticipated for ISAC are to review activities and estimate potential outcomes, to review and confirm the list for the second year of ISAC activities, and to review and start the activities of the second-tier countries (Bangladesh, the Democratic Republic of the Congo, Mozambique, Myanmar, Rwanda, Sri Lanka, the United Republic of Tanzania, and Zambia).

2.5 DEWG subgroups

2.5.1 Childhood TB

The progress and achievements of the Childhood TB Subgroup, established in 2003, were presented. The goal of the subgroup is to decrease the global burden of mortality and morbidity caused by TB in children. The objectives are to promote research and policy development, formulate and implement guidelines, mobilize human and financial resources, and collaborate with partners working in relevant fields – including maternal and child health, the Expanded Programme on Immunization (EPI), and HIV/AIDS. The main activities are:
• developing guidance for NTPs, on promoting childhood TB prevention and care;
• advising on acceptable case definitions and recording of childhood TB cases
• advising on child-friendly formulations and preparations of anti-TB drugs; and
• developing a proposal for implementation and research activities.

2.5.2 Laboratory capacity strengthening

The activities conducted in 2004 by the Subgroup on Laboratory Capacity Strengthening were presented. The group performed assessments in Bangladesh, Kenya, Pakistan, Romania, and Uganda. Assessments were planned for the Russian Federation (November 2004), Indonesia (December 2004) and Egypt (December 2004).

Other activities included development of the global strategy to improve the capacity of TB diagnostic services, revision of the laboratory assessment tool, and a review (and repackaging) of available international and national training materials. Members of the subgroup participated in several NTP reviews in collaboration with partners, translated the external quality assessment component of the *AFB Smear Microscopy Guidelines* into French, organized laboratory management training for managers of the national reference laboratories from the WHO Eastern Mediterranean Region, and organized the annual subgroup meeting in Paris in conjunction with the 5th meeting of the DEWG and the IUATLD World Conference on Health.

2.5.3 Public-Private Mix (PPM) DOTS

The activities of the Subgroup on PPM DOTS were presented. Two reports were published in 2003–2004: one on the cost-effectiveness of PPM, and a second on a cross-site analysis entitled *What makes PPM work?* The 2nd PPM-DOTS Subgroup meeting was held in India in February 2004. Intensified support for PPM-DOTS has been given to countries through missions to Bangladesh, China, India, Kenya, and Myanmar. A PPM-DOTS surveillance system is being piloted in 12 of 14 cities, scaling up PPM DOTS. Draft PPM guidelines are in preparation.

Since 1995, more than 40 PPM-DOTS projects have been initiated and more than 20 000 patients evaluated. Treatment success of new sputum-smear-positive cases in the private sector has increased substantially from baseline in a number of evaluated projects (i.e. Bangladesh, India, Indonesia, Myanmar, Nepal, the Philippines, and the Republic of Korea). Economic analysis has shown that patient costs have been reduced by more than 60% in PPM DOTS projects in Hyderabad and New Delhi, India, compared with private non-PPM DOTS. There is a high level of sustainability in PPM-DOTS projects such as Hyderabad (since 1995), the Damien Foundation in Bangladesh (since 1997), Nepal (since 1998), and several projects in India and the Philippines (which have been operational for between three and five years).

The way forward for the subgroup includes: continuing to decentralize and strengthen technical capacity for PPM DOTS; mainstreaming PPM DOTS into DOTS expansion; disseminating and emphasizing the international standard of TB care; facilitating resource mobilization through strengthening the PPM-DOTS component in GFATM proposals; exploring PPM DOTS-Plus and PPM for TB/HIV; developing documentation and guidelines for various PPM strategies (e.g. medical colleges, NGOs, individual private practices), and continuing operational research on PPM and poverty-related MDGs.
3. Evolution of DOTS

3.1 TB care for all: evolution of the DOTS strategy

Substantial progress has been made towards the 2005 global targets: the case-detection rate is 43% and the treatment success rate is 82%. The best forecast suggests that the treatment success global target will be achieved; however, DOTS expansion must be accelerated to reach the case-detection target.

The main directions for accelerating DOTS expansion and for adapting outreach to all are as follows.

- Continue to expand and sustain DOTS achievements, supporting countries in building capacity and mobilizing resources, within strengthened health systems.
- Advocate for:
  - DOTS, as the recognized public health strategy for TB control; and
  - the importance of individual patient care within DOTS.
- Engage all care providers, public and private, to increase access and use of an essential standard of care – especially among the poorest.
- Promote community participation and mobilize societies to increase:
  - demand for proper care; and
  - involvement in care.
- Adapt DOTS to high-HIV and multidrug resistant (MDR)-TB settings, and strengthen capacity to diagnose and manage sputum-smear-negative TB and drug-resistant cases.
- Strengthen monitoring and evaluation for problem-solving and for measuring achievements vis-à-vis World Health Assembly and MDG targets.
- Sustain the Stop TB Partnership and its working groups.

In addition to the essential public-health approach to TB, a care approach is also needed. Patient care to cure and prevent TB is the ultimate goal of DOTS. The foundation of DOTS is effective patient care – to alleviate suffering, as well as to control and prevent TB in a community. A standard of care for TB exists within DOTS, but that standard needs further promotion among all care providers. Stated simply, each care provider – public or private – should:

- diagnose TB quickly (i.e. bacteriological confirmation);
- treat TB properly (i.e. short course chemotherapy (SCC) and treatment support); and
- report TB cases and treatment outcomes.

3.2 Developing an international standard for TB care

The following resolution (WHA58.14) was presented and adopted by the Fifty-eighth World Health Assembly in May 2005.

The 58th World Health Assembly—stressing the importance of the engagement of the full range of health providers in delivering the international standard of tuberculosis care in line with the strategy of DOTS—encourages all Member States to ensure that all TB patients have access to the universal standard of care based on proper diagnosis, treatment and reporting consistent with the DOTS strategy by promoting both supply and demand …

A standard is needed to bridge the apparent gap between tuberculosis care and tuberculosis control, and to provide a framework for both public-sector and private-sector providers that builds on the principles of DOTS. The Tuberculosis Coalition for Technical Assistance (TBCTA), which is
funded by USAID, will fund a 12-month project to develop this universal standard of care by an appointed steering/writing committee of 15 members. The launch of the final consensus document is planned for the IUATLD Conference to be convened in October 2005.

3.3 **The second Global Plan to Stop TB (2006–2015)**

The second Global Plan to Stop TB will build on the first Global Plan and Progress Report. This second Global Plan is needed to provide:

- a vision of what can be achieved;
- a road map to achieve targets;
- a tool for advocacy and fund-raising;
- support for long-term national planning; and
- stimulation for research and development.

The key features of the second Global Plan lie in its provisions which:

- lead to the 2015 Millennium Development Goals;
- have a 10-year time frame;
- build on the first Global Plan and Progress Report;
- are complementary to the MDGs TB Working Group report;
- are consistent with the 2005 World Health Assembly resolution;
- support country needs for long-term planning and financial sustainability;
- develop strategic directions set out by the 2nd ad hoc Committee on the TB Epidemic;
- are based on contributions of the Stop TB working groups.

The development of the plan is coordinated by the Stop TB Partnership Secretariat, guided by a steering committee and based on contributions of the seven Stop TB Partnership working groups (DOTS Expansion, DOTS-Plus, TB/HIV, Drugs, Diagnostics, Vaccines, and Advocacy and Communications). Each working group will develop its work plan as a contribution to the Global Plan, facilitated by the secretariat of each working group. The second Global Plan will be finalized by September 2005 and launched by the end of 2005.

4. **Laboratory services in the 22 HBCs**

All 22 HBCs were asked to develop and prepare a poster presentation according to a template. The theme of the presentation was laboratory services and issues. These issues were presented and discussed in the following six groups.

- Group 1: Afghanistan, Brazil, Nigeria, and the Russian Federation.
- Group 2: Mozambique, Pakistan, and Thailand.
- Group 4: South Africa, Uganda, and Zimbabwe.
- Group 5: Cambodia, India, the Philippines, and Viet Nam.
- Group 6: China, the Democratic Republic of the Congo, Ethiopia, and Indonesia.

Summaries of the group discussions are presented in Annex 1.

4.1 **Laboratory issues: proposed action by the DEWG**

The group discussions led to consensus of the following proposed actions to be taken by the DEWG.
Advocacy strategy to enhance political commitment: advocate to all partners (including governments, NTPs, and technical and financial agencies) the important role of the laboratory in TB control. Increase resources for laboratories (e.g. GFATM applications, World Bank, bilateral donors).

Strengthening of the human resources component: ensure that enough human resources are available. Ensure competency of staff at all levels through standardized training, improved supervision and evaluation activities, and development and implementation of standard operating procedures.

External quality assurance (EQA): ensure high-quality supervision and feedback mechanisms. Develop and implement slide re-checking/proficiency schemes. Link with the supranational reference laboratory.

Procure high-quality equipment and laboratory supplies.

Improve communication between the NTP and laboratory management: involve national reference laboratories in planning and budgeting. Invite laboratory managers to NTP meetings.

Facilitate field evaluation of new diagnostic tools.

It is recommended that the DEWG Subgroup on Laboratory Strengthening Capacity should:
- continue assessing laboratory systems in the HBCs;
- develop standardized training packages;
- strengthen the managerial capacity of national reference laboratory managers (training of trainers).

5. Key issues in DOTS implementation

5.1 Human resources: the role of nurses

Some challenges faced by nurses in TB control include the lack of nursing guidelines and research evidence; the lack of an international voice; and the large variation in resources, environment, and qualifications. Nurses should play an important role in TB control, because they work globally and they share common ideas and values.

Nurses can play a key role in obtaining the goal of at least 70% case detection and 85% treatment success in a community for a number of reasons. They are a first point of call in primary care services, and are involved directly in health education. They can follow the patient from presentation to registration, and perform many of the recording and reporting functions of a health facility.

Nurses may not be reaching their full potential in TB control because of the lack of strategic level representation, research evidence, and consistent training and materials. The TB control community should take full advantage of the potential of nurses by identifying leaders in the field and developing research and training opportunities.

5.2 Collaboration with other health-care providers

5.2.1 Scaling-up PPM DOTS in India

The Revised National TB Control Programme (RNTCP) of India has expanded implementation of DOTS from 87 districts (with a population of 188 million) in the first quarter of 2000, to 521 districts (906 million) in September 2004. The first PPM model began in Hyderabad in 1995; and between 2000 and 2003, PPM models were established in New Delhi, Kannur, Kollam, Mumbai, and the tea
gardens of the north-east. In 2002, private practitioners schemes were published, and in 2003 new PPM-DOTS activities were initiated in many districts.

An intensified PPM scaling-up began in 14 urban sites in 2003. By September 2004, more than 160 medical colleges, 800 NGOs, 5000 private practitioners and 80 corporate houses were involved in DOTS. Health-care facilities under ministries other than that of health have started implementing DOTS; these include the Ministries of the Railways, Employees State Insurance, and Mining, Coal, and Shipping.

In the second and third quarters of 2004, 61% of new sputum-smear-positive cases were detected by health providers, 18% by medical colleges, 8% each by private practitioners and NGOs, 4% by government facilities, and 0.2% by the corporate sector. With the scaling-up of PPM-DOTS projects, case detection and treatment success are on course to meet the 2005 global targets.

5.2.2 Business sector contributions to the global effort to Stop TB
The global health initiative is a partnership between the World Economic Forum, WHO (specifically Roll Back Malaria and the Stop TB Partnership) and UNAIDS, to increase the quality and quantity of private sector activity to fight HIV, TB, and malaria. Until two years ago, however, there was no real collective business action against TB.

The business sector should be involved in TB control because companies can reach related but diverse groups (e.g. workers, families, surrounding communities, suppliers and contractors, and consumers), bring expertise to people (through communication and marketing, distribution, project management, and research and development), and provide resources (in-kind contributions, people and cash). The private sector can help national TB programmes by reaching different segments of the population, often in difficult-to-reach rural, remote or dense urban areas. Synergistic outcomes include increased case detection and a maintained treatment success rate, better NTP country coverage and more available public health and private employers services. Two examples of successful business sector involvement in TB control are Chevron Texaco in Angola and the Indian Business Alliance to Stop TB. Within a 12-month period in Angola, the programme has detected an additional 555 cases with 92% treatment success. The Indian programme has led to raised awareness about TB, the implementation of DOTS in many workplaces, and a growing number of member companies.

5.2.3 Strengthening TB control through social franchising: experiences from Myanmar
Social franchising of DOTS has started in Myanmar using the Sun Quality Health (SQH) franchise through Population Services International/Myanmar (PSI). The SQH franchise has 470 clinics with over 500 doctors trained in 8 of 14 states/divisions, covering a combined township population of more than 17 million. The SQH franchise has had positive results in the reproductive health community and this model was used to integrate DOTS into SQH.

PSI worked with the national tuberculosis programme to develop the social franchising strategy. The NTP defined diagnostic and treatment protocols and private provider roles; reviewed training materials; provided laboratory training; conducted laboratory quality assurance and monitoring visits; provided fixed-dose combination (FDC) drugs; and facilitated government approvals. PSI defined the strategy for engaging private providers; selected and trained private providers; selected laboratories; facilitated laboratory quality assurance; collected data; branded and packaged FDC drugs; and designed, pre-tested, and produced print and video communications. In the first seven months of the project, 102 private providers were trained in DOTS; seven private laboratories were provided with training and accredited; and 1500 cases were detected (40% new smear positive). There are signs of a positive impact on overall case detection.
5.2.4 National partnership: Uganda

There has been an upward trend in TB case notifications in Uganda since 1995. The idea of a Stop TB Partnership came about as the need to coordinate the various activities of TB control stakeholders became apparent. The partnership has a number of objectives including those to:

- raise the profile of TB as a major public health problem in Uganda;
- improve the coordination of efforts by various stakeholders;
- harmonize work plans for a concerted effort to reach 2005 global targets and MDGs;
- mobilize extra financial and human resources;
- guide relevant operational research for TB control.

A commitment by the Minister of Health to meet global 2005 targets and the need to utilize available funds from CIDA, FIDELIS, GFATM, and USAID created the impetus to start the process of developing a partnership. WHO has offered to house the partnership and an interim executive secretary has been appointed. Terms of reference have been developed and approved. To date, several technical and financial partners have agreed to the partnership, with more expected to join. The partnership was to be launched in December 2004.

5.3 Important issues for DOTS expansion

5.3.1 TB and poverty

The World Development Report for 2004 summarized the fact that services in general fail for poor people within the contexts of access, quantity, and quality, but that services do work when the poor are put at the centre of service provision. Specifically, TB control programmes do not always reach the poor, but can be improved by putting TB control on the agenda in poverty reduction strategy papers, by accelerating development and implementation of pro-poor strategies, and by pursuing research and response on poverty.

The Network for Action on TB and Poverty is a platform for TB-control and poverty experts to coordinate actions in support of countries and the poor. The objectives of the network are to:

- assist pro-poor mainstreaming in DOTS expansion and TB;
- foster research to inform TB control operations and policy control; and
- advocate pro-poor approaches using DOTS and link up with other initiatives and funding.

The network will be governed by the Core Group on TB and Poverty, a subgroup of the DEWG. Terms of reference for the secretary have been developed and guidelines for NTP managers on TB and poverty will provide strategic and practical guidance to countries.

5.3.2 TB Diagnostic Kits Initiative

Rapid DOTS expansion to meet the 2005 global targets requires reliable and quality-assured laboratory diagnosis of TB. Supply constraints at the country level often threaten appropriate diagnosis, and have led the GDF to develop laboratory kits. Preliminary research has shown that laboratory kits may benefit HBCs by providing standardized high-quality products at cheaper prices, an easier procurement process, and a reduced incidence of stock outages and service disruptions.

Proposed laboratory kits include microscope kits, consumables kits (with ready-to-use ZN stains for 1000 smears), sputum-collection containers, and equipment starter kits. In-country piloting of kits will take place in the Congo (Brazzaville), Nigeria, and Sierra Leone. This piloting will evaluate the application process, provide comprehensive data collection, determine sustainability of kits, and evaluate opinions of NTP and laboratory staff.

5.3.3 Tuberculosis and HIV – future directions

The fourth meeting of the DEWG held in 2003, concluded that joint TB/HIV activities are necessary for TB control, because HIV drives TB incidence and mortality in high-HIV prevalence areas, TB is a
significant cause of mortality among HIV/AIDS patients, and – where the incidence of HIV is high and rising – DOTS alone is insufficient to control TB.

TB/HIV collaborative activities will establish mechanisms for collaboration, decrease the burden of TB in people living with HIV/AIDS, and decrease the burden of HIV in TB patients. The fourth meeting of the TB/HIV Working Group was held in September 2004, with the theme "Two diseases – one patient: scaling-up prevention and treatment for TB and HIV". The conclusions of that meeting were as follows.

- Significant progress has been made since Montreux.
- Current movement is good, but there is still a long way to go.
- The HIV-activist community is engaging in the effort.
- The partnership is expanding, and support for joint TB/HIV activities is coming from the African Union, the Prime Minister of Ethiopia, and the Director of the Centres for Disease Control and Prevention (CDC) in the USA.
- Focus is now on implementation in countries.
- Systems for measuring progress need to be strengthened.

Future directions of the TB/HIV Working Group include country implementation (e.g. technical assistance, expansion of evidence base, GFATM round 5 applications), advocacy at the country level (through supporting alliance with advocates), increased partnership activity, new tools, and sustainable funding.

### 5.4 Integrating DOTS-Plus components into DOTS programmes

The final session of the fifth meeting of the DEWG included a presentation on the magnitude of the MDR-TB problem, the availability of second-line drugs, the Green Light Committee (GLC) mechanism, and future plans and challenges. Based on resistance surveys in 64 countries and predictive data from 72 countries, the number of estimated new cases of MDR-TB in 2000 was 273,000. From June 2000 to August 2004, the GLC held 26 meetings and reviewed 38 applications – over 8000 patients are enrolled in 25 approved projects.

Advantages to applying the GLC mechanism are many, including the following:
- access to a continuous supply of quality-assured, low-cost drugs;
- access to technical assistance;
- access to an external monitoring mechanism;
- increased rational use of drugs;
- creation of wide evidence base for policy development;
- ensured consolidation of DOTS as the strategy to control TB.

While DOTS-Plus is more complicated than DOTS, it is feasible under routine programme conditions. Indeed, mainstreaming of DOTS and DOTS-Plus is already taking place in many settings. Future plans include development of new guidelines, training courses and field training; increased technical assistance; improved laboratory capacity-building; maintaining and upgrading GLC operations; resource mobilization; and continued policy development.

Three examples of countries in different stages of DOTS-Plus were presented.

1. **The United Republic of Tanzania.** DOTS-Plus preparation phase.
   The set of essential conditions (determined by the GLC as prerequisite to the introduction of DOTS-Plus into the country) was described, and the progress the country had been making to meet these conditions was assessed.

2. **The Philippines.** DOTS-Plus expansion and mainstreaming.
The status of DOTS-Plus in the country, and the issues and challenges involved in turning the DOTS-Plus pilot project into policy, were detailed.

3. **Latvia.** Full implementation and integration.
   A presentation was made on how full DOTS-Plus implementation has positively affected TB control and MDR-TB in the country.

6. **Conclusions**

The conclusions of the 5th meeting of the DEWG – presented by its Chairman – were as follows.

- Important laboratory issues should be addressed in all countries for further effective TB control and DOTS expansion. Proposals for action to be taken by the DEWG include:
  - countries must increase resources for laboratories;
  - laboratory human resources (quantity and quality) must be strengthened;
  - external quality assurance systems must be established;
  - high-quality equipment and laboratory supplies are needed;
  - collaboration is necessary between the NTP and laboratory managers;
  - standardized training packages must be developed;
  - managerial capacity of national reference laboratory managers needs to be strengthened;
  - field evaluation of new diagnostic tools must be facilitated.

- DOTS has evolved from the mid-1990s. The first standardized framework for TB control and DOTS branding were introduced to the expanded DOTS framework in early 2000.

- The TB control strategy used today is based on the *Expanded DOTS framework for TB control*, published in 2002. That framework includes the following approaches.
  - political commitment;
  - diagnosis with bacteriology confirmation – microscopy, culture and drug-susceptibility testing (DST);
  - standardized treatment under proper case-management conditions, including directly observed treatment (DOT);
  - uninterrupted drug supply to the patient;
  - an adequate recording and reporting of cases and treatment outcomes.

- The main directions needed to accelerate DOTS expansion and reach all patients involve:
  - expanding and sustaining DOTS achievements within strengthened health systems;
  - emphasizing, first, DOTS as the public health strategy for TB control, and second, the importance of individual patient care with DOTS;
  - improving diagnostic capacity and reliability;
  - engaging all care providers – public and private – to increase access and use of standard of care, especially among the poorest;
  - promoting participation of community and social mobilization for TB care;
  - streamlining TB/HIV activities and treatment of MDR-TB with DOTS programme activities;
  - strengthening monitoring and evaluation for problem-solving and to measure achievements vis-à-vis World Health Assembly and MDG targets;
- increasing communication among Stop TB Partnership working groups;

- The DEWG must continue to link with the GFATM, World Bank, and bilateral and multilateral donors, to broaden the scope of activities, which include:
  - laboratory strengthening
  - PPM-DOTS (engaging all health-care providers)
  - ISAC (human resources/capacity building)
  - GDF (quality drug supply)
  - advocacy, communication, and social mobilization
  - building and funding partnerships
  - drug resistance surveillance (DRS) and MDR-TB
  - TB/HIV
  - monitoring (internal, external, MDGs).

7. Next meeting

The next meeting of the DEWG will be held jointly with the TB/HIV Working Group and the DOTS-Plus for MDR-TB Working Group and will take place from 15 to 17 October in the Palais des Congrès, Versailles, France. A symposium will be held on 18 October as part of the 36th Union World Conference on Lung Health of the IUATLD.
Annex 1
Summaries of group discussions on laboratory services in the 22 HBCs

Group 1. Afghanistan, Brazil, Nigeria, and the Russian Federation

DOTS coverage varies in these countries from 17% in the Russian Federation to 60% in Nigeria, but remains low in all. The case-detection rate also varies widely – from 20% in Afghanistan to 81% in Brazil – although the DOTS detection rate is low in all countries. All countries rely on chest x-ray for diagnosing sputum-smear-negative patients. Brazil and the Russian Federation also refer the patient for culture; however, the capacity and quality assurance (QA) of culture in the Russian Federation is inadequate.

Data on MDR-TB is lacking in both Afghanistan and Nigeria. Brazil has a low percentage of patients with MDR-TB because they use fixed-dose combination drugs. Parts of the Russian Federation have high rates of MDR-TB (3–11% in new cases; 26–30% in retreatment cases).

All of these countries face challenges to their laboratory services.

- **Afghanistan.** The main issue is the lack of a reference laboratory. Overall, there are few laboratories and diagnostic centres. Those that do exist lack sufficient quantity and quality of staff and quality assurance. Increased government commitment is needed.

- **Brazil** has a centralized laboratory network with approximately 4000 local laboratories which are performing sputum-smear microscopy, 137 laboratories which are performing culture, and 33 which are capable of performing drug susceptibility testing (DST). The main challenge is the development of an information system to cover the large number of laboratories in the country. The recent decentralization of the health system did not take laboratories into account, which has resulted in shortages of funding for the laboratory network.

- **Nigeria** has a laboratory network with over 500 microscopy centres. However, quality assurance of sputum-smear microscopy is a major challenge due to lack of funding. Government commitment needs to be increased. The establishment of two national reference laboratories is a priority.

- **The Russian Federation** has a weak laboratory network that needs better links to the five federal-level laboratories. Currently, an administrative reform is in progress that will have effects at the laboratory level. There is a continued lack of human resources and quality assurance, and necessary training is needed.

In general, national reference laboratories and reference laboratories below the national level are either weak or do not exist. Information systems and human resource capacities are inadequate. Supplies and equipment are insufficient. All countries need to establish or improve their quality assurance systems.

Group 2. Mozambique, Pakistan, and Thailand

The case-detection rate varies from 32% in Pakistan, to 55% in Mozambique, to a high of 81% in Thailand. All countries have treatment success rates of approximately 75–78%. Mozambique and Pakistan diagnose smear-negative patients through clinical symptoms and chest x-ray. Thailand diagnoses some of its smear-negative cases with culture in the national laboratory. All three countries have national reference laboratories with DST capability.

Additionally, some private laboratories in Pakistan and seven laboratories in Thailand also perform drug susceptibility testing. All of these countries face challenges to their laboratory services.
• **Mozambique.** There are constraints to human resources development and training, and additional reference laboratories are needed in the central and northern parts of the country. Quality assurance remains inadequate, and the laboratory capacity of peripheral health centres needs to be improved. Planned activities for 2005 include establishing two new reference laboratories and exploring ways to increase human resources for laboratory services.

• **Pakistan.** An intermediate-level laboratory service and standardization of training and laboratory supplies are needed. Quality assurance remains inadequate, and human resources are lacking. In 2005, Pakistan plans to implement external quality assurance (EQA) and develop an intermediate laboratory network.

• **Thailand.** There is good capacity for smear microscopy, although culture capacity needs to be strengthened at provincial hospitals. Building capacity for DST in the regions also remains a challenge. Training is needed for non-licensed staff for smear microscopy. In 2005, Thailand will build additional capacity for culture and DST, and explore ways to incorporate rapid diagnostic methods for detection of *M. tuberculosis* and drug resistance.

**Group 3. Bangladesh, Kenya, Myanmar, and United Republic of Tanzania**

The case-detection rate varies from 41% in Bangladesh to 74% in Myanmar. All four countries have treatment success rates at or above 80%. All of these countries face challenges to their laboratory services.

• **Bangladesh.** The major challenges are to increase and maintain high levels of commitment at policy levels for microscopy quality, to supervise and extend the implementation of QA of sputum microscopy, and to expand acid-fast bacilli (AFB) culture and DST for drug resistance surveillance. The planned priority actions in 2005 are to build capacity through basic and refresher training, expand diagnostic services by establishing new microscopy centres in all Upazilas with populations over 300 000, and implement quality assurance of sputum microscopy in all urban and rural diagnostic centres.

• **Myanmar** lacks quantity and quality of staff in the laboratory services, has a weak EQA system, and weak overall supervision of laboratories. The planned priority actions in 2005 are human resources development, strengthening of the EQA system, strengthening of culture and DST at the national reference laboratories in Yangon and Upper Myanmar, and expansion of culture facilities to four state/divisional laboratories.

• **Kenya.** The major challenge is inadequate human resources, which is hampering the decentralization process. There is also an inadequate budgetary allocation for supervision of laboratory services. The priorities for laboratory services in 2005 are to strengthen the EQA system and supervision, increase the laboratory technical staff to support decentralization, expand the linkage between public and private laboratory networks, and improve the technical capacity of the central reference laboratory.

• **The United Republic of Tanzania** has a shortage of qualified laboratory staff and unsatisfactory implementation of the QA programme for smear microscopy. In 2005, the priorities are drug resistance surveillance, improvement of the quality of supervision of peripheral laboratories, minimization of laboratory cross-contamination, and validation of "Ora-Quick" for TB/HIV surveillance.

In general, the main constraints within these countries are human resources (quantity and quality), quality assurance of smear microscopy, and equipment/supplies.
Group 4. South Africa, Uganda, and Zimbabwe

The case-detection rate varies from 47% in Zimbabwe to 53% in Uganda to over 90% in South Africa. All three countries have treatment success rates below the 85% target: Uganda at 61%, South Africa at 65%, and Zimbabwe at 70%. The estimated percentage of MDR-TB in new cases is below 2% for all these countries. The challenges faced by the laboratory services, and planned actions include the following.

- **Uganda.** The main challenges include the lack of an EQA system and lack of trained technicians. The priority actions for 2005 include drug resistance surveillance, EQA implementation, and recruitment of staff.
- **South Africa** has a reference laboratory but it is not integrated with the NTP. The turn-around time for sputum smear microscopy needs to be improved. The country plans to establish a national reference laboratory and improve turn-around times.
- **Zimbabwe** lacks trained laboratory staff and improvements are needed in supervision. The planned priority actions for 2005 are to establish and strengthen the EQA system, strengthen capacity for culture and DST, and improve supervision.

Group 5. Cambodia, India, Philippines, and Viet Nam

DOTS coverage is high in all four countries: 73% in India, 83% in Cambodia, and 100% for both the Philippines and Viet Nam. With the exception of Viet Nam, these countries have not met the global target of 70% case detection (54% in India – 69% in DOTS areas, 59% in Cambodia, and 61% in the Philippines). Treatment success rates are above the global target in all countries (in all DOTS areas in India).

Since 2000, drug-resistance surveys have been completed in Cambodia, the Philippines, and Viet Nam. The percentage of TB/HIV dual infection varies from 3.2% in Viet Nam, to 4.6% in India, to a high of 12% in Cambodia. All countries are either implementing or in the planning stages of PPM-DOTS projects. All of these countries face challenges to their laboratory services.

- **Cambodia.** Procurement of equipment and supplies, quality of staff, and low salaries are the main challenges.
- **India.** Shortage of laboratory technicians and capacity building are the main challenges.
- **The Philippines.** Guidelines for the laboratory network and strict definitions of laboratory functions are needed.
- **Viet Nam.** An EQA system needs to be implemented.

EQA has been implemented in Cambodia, India, and the Philippines. Viet Nam uses traditional QA. All countries have functioning national reference laboratories for QA, training, monitoring, and surveillance. Smear microscopy is the priority for all countries, though culture is performed for specific purposes. However, all countries need better definitions or criteria for the use of culture.

Group 6. China, Democratic Republic of the Congo, Ethiopia, and Indonesia

The case-detection rate varies from 40% in Indonesia, to 46% in Ethiopia, to 65% in the Democratic Republic of the Congo. Treatment success rates are above the global target only in China (92%). That rate is 82% in Ethiopia and 78% in the Democratic Republic of the Congo. The percentage of MDR-TB in new cases varies from 1.3% in Ethiopia to 7.6% in China.

- **China.** The government is highly committed to improving laboratory services for DOTS expansion. There are one central reference laboratory and 31 provincial reference laboratories.
- **The Democratic Republic of the Congo.** In the one national reference laboratory and 20 provincial laboratories, services are challenged since 50% of smear-positive TB patients are HIV-positive. There is also instability among the health staff due to country conflict and war.
• **Ethiopia.** Intermediate management of laboratory services is greatly needed. Standardized training, which includes training modules and regional training teams, has been established.

The main challenges for laboratory services in all four countries include shortage of trained laboratory staff, absence or weakness of laboratory networks at the regional and provincial levels, supply problems, and absence or weakness of QA systems. Plans to address these challenges include human resources development, establishing and strengthening national reference laboratories, supportive supervision of intermediate and peripheral laboratories, operational research, and focused attention to logistics.
Annex 2
Agenda

27 October 2004 – by invitation

7:30–8:30 Registration

8:30–9:15 Welcome
K. Shah (DEWG Chair)

TB care for all: evolution of DOTS strategy
M. Raviglione (Director, WHO/STB)

Evidence for standard of care
P. Hopewell (ATS/TBCTA)

9:15–10:00 Progress towards the 2005 targets and next steps
C. Watt (WHO, HQ)

D. Maher (WHO, HQ)

Discussion

10:00–10:30 Report from the secretariat: Achievements in 2003/2004
L. Blanc (WHO, HQ)

Discussion

10:30–11:00 Coffee break

11:00–11:45 Reports from the DEWG subgroups

11:00–11:15 Childhood TB
R. Gie (South Africa)

11:15–11:30 Laboratory strengthening
F. Portaels (Belgium)

11:30–11:45 PPM
K. Lönnroth (WHO, HQ)

11:45–12:15 Quality of care for all
F. Matthys (MSF)

12:15–13:30 Lunch

13:30–15:30 Country presentations and group discussions on increasing case detection with a special focus on laboratories.

15:30–16:00 Coffee break

16:00–18:00 Report from the group discussions, including outline of needs to strengthen laboratories.

<table>
<thead>
<tr>
<th>Group</th>
<th>Room</th>
<th>Countries</th>
<th>Facilitator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>351</td>
<td>Afghanistan, Brazil, Nigeria, Russian Federation</td>
<td>S. Bacheller (USAID)</td>
</tr>
<tr>
<td>Group 2</td>
<td>330/331</td>
<td>Mozambique, Pakistan, Thailand</td>
<td>C. Wells (CDC)</td>
</tr>
<tr>
<td>Group 3</td>
<td>332/333</td>
<td>Bangladesh, Kenya, Myanmar, United Republic of Tanzania</td>
<td>C. Hanson (PATH)</td>
</tr>
<tr>
<td>Group 4</td>
<td>336/337</td>
<td>South Africa, Uganda, Zimbabwe</td>
<td>A. Trébucq (IUATLD)</td>
</tr>
<tr>
<td>Group 5</td>
<td>353</td>
<td>Cambodia, India, Philippines, Vietnam</td>
<td>I. Onozaki (Chiba Foundation)</td>
</tr>
<tr>
<td>Group 6</td>
<td>352A</td>
<td>China, Democratic Republic of the Congo, Ethiopia, Indonesia</td>
<td>J. Broekmans (KNCV)</td>
</tr>
</tbody>
</table>
28 October 2004 – open meeting

8:30–9:00  Welcome  K. Shah (DEWG Chair)  
            Report of day 1  N. Billo (IUATLD)  
            C. Basri (Rapporteur)  

9:00–9:30  Progress towards the Millennium Development Goals  C. Dye (WHO)  

9:30–10:00  Human resources: the role of nurses in TB control  
            Discussion  G. Williams (IUATLD)  

10:00–10:30  Coffee break  

Session Chair: M.J. Chakaya (Kenya)  
10:30–11:00  Report from the secretariat: Intensified support and action countries (ISAC) initiative  
            Discussion  K. Shah (DEWG Chair)  

11:00–12:30  Collaboration with other health-care providers  
11:00–11:15  1. Scaling up PPM  L.S. Chauhan (India)  
11:15–11:30  2. TB management in the workplace  F. Boldrini (WEF)  
11:30–11:45  3. Strengthening TB control through social franchising/marketing: experiences from Myanmar  G. Stallworthy (PSI)  
11:45–12:00  4. National partnership  F. Adatu-Engwau (Uganda)  
12:00–12:30  Discussion  

12:30–13:45  Lunch  

13:45  Working groups of Stop TB Partnership  
      M. Espinal (Executive Secretary, STB Partnership)  

Session Chair: E. Luna (Brazil)  
13:45–14:15  TB and poverty  
            P. Gondrie (KNCV)  
            M. van Cleeff (KNCV)  
14:15–14:30  The Global TB Drug Facility's diagnostic kits for AFB microscopy  
            C. Mundy (MSH)  
14:30–15:30  TB/HIV: future directions after the 4th Working Group Meeting in Addis Ababa  
            P. Nunn (WHO, HQ)  
15:30–16:00  Coffee break  

Session Chair: J. Lagahid (Philippines)  
16:00–17:30  Integrating DOTS-Plus components into DOTS programmes  
            K. Lambregts (WHO, HQ)  
16:30–16:45  1. United Republic of Tanzania: DOTS-Plus preparation phase  
            S. Egwaga (United Republic of Tanzania)  
16:45–17:00  2. Philippines: DOTS-Plus expansion and mainstreaming  
            T. Tupasi (Philippines)  
            R. Vianzon (Philippines)  
17:00–17:15  3. Latvia: full implementation and integration  
            V. Leimane (Latvia)  
17:15–17:30  Panel discussion  

17:30–18:00  Conclusions  K. Shah (DEWG Chair)
Annex 3
List of participants

Afghanistan

Professor Mir Azizullah Akghar
Director, National TB Programme
c/o WHO Representative in Afghanistan
Street no. 13
Wazir Abkar Khan (near Pakistan Embassy)
Kabul

Dr Abdul Wadood Haidari
Deputy Director, National TB Programme
c/o WHO Representative in Afghanistan
Street no. 13
Wazir Abkar Khan (near Pakistan Embassy)
Kabul

Bangladesh

Dr Vikarunnessa Begum
Deputy Programme Manager
TB/Leprosy Control Programme
Leprosy Hospital Compound
DGHS, Mohakhali
1212 Dhaka

Brazil

Dr Maria Candida de Soza Dantas
Ministerio de Saúde
Secretaria de Vigilancia em Saúde
Esplanada dos Ministerios
Bloco G, Ed. sede, 5 andar, Gabinete
CEP 70058-900, Brasilia-DF

Dr Expedito Luna
Director de Epidemiologia
Secretaria de Vigilancia em Saúde
Ministerio da Saúde
Esplanada dos Ministerios
Bloco G, sala 155
70058-900, Brasilia-DF

Dr Joseney dos Santos
Director do Centro Nacional de Epidemiologia - CENEPI
Fundação Nacional de Saúde
Ministerio de Salud do Brasil
Esplanada dos Ministerios, Bloco G
Ed. sede, 5 andar, Gabinete
70058-900 Brasilia-DF

Cambodia

Ms Ton Chavivan
Acting Chief
CENAT TB Laboratory
Ministry of Health
Street 278/95, Sangkat Boeng Keng Kang 2
Chamkarmorn, Phnom Penh

Dr Mao Tan Eang
Director
National Center for TB and Leprosy Control (CENAT)
Street 278/95 Boeng Keng Kang 2
Chamkarmorn, Phnom Penh

China

Dr Xiao Donglou
Deputy Director
Department of Disease Control and Prevention, Ministry of Health
1, Xi Zhi Men Wai Nan Lu
Beijing 10044

Dr Duanmu Hongjin
Beijing Tuberculosis and Thoracic Tumour Research Institute
No. 97 Ma Chang
Tong Zhou District
Beijing 101149

Dr Liu Jianjun
Director
National Center for TB Control and Prevention
CDC China
No. 27 Nanwei Road
Xuanwu District
Beijing 100050

Democratic Republic of the Congo

Dr Etienne R. Bahati
Director
National Tuberculosis Program
PO Box 12.706
Avenue Kabinda, face RTNC
Kinshasa
Dr Georges Kabuya Mutala  
National Tuberculosis Program  
PO Box 12.706  
Avenue Kabinda, face RTNC  
Kinshasa

**Ethiopia**

Dr Eshetu Lemma  
Director, National Reference Laboratory  
TB and Leprosy Control Programme  
Ministry of Health  
PO Box 1234  
Addis Ababa

Dr Zerihun Tadesse  
Manager, TB and Leprosy Control Programme, Ministry of Health  
PO Box 1234  
Addis Ababa

**India**

Dr Lakhbir Singh Chauhan  
Deputy Director General, TB  
Ministry of Health and Family Welfare  
Government of India  
523 C, Nirman Bhavan  
110 011 New Delhi

**Indonesia**

Dr Carmelia Basri  
Head, Standardization & Partnership Section, National TB Control Programme  
Ministry of Health  
Janal Percetakan Negara No. 29  
Gedung B, Lantai 4  
Jakarta Pusat 10560

Dr Siti Nadiia Tarmizi  
National TB Control Programme  
Directorate CDC & EH,TBC Subdirectorat  
B Building, 2nd floor  
Janal Percetakan Negara No. 29  
Jakarta 10560

Dr Gunawan Yamin  
Head, Subdirectorat of Microbiology  
Directorate of Health Laboratory  
Directorate General of Medical Care  
Ministry of Health  
Jalal H.R. Rasuna Said Blok X-5 Rav 4–9  
Jakarta 12950

**Kenya**

Dr Jeremiah Muhwa Chakaya  
Head  
National Leprosy and TB Programme  
Ministry of Health  
PO Box 20781  
Nairobi

Mr Mike Mayabi  
Head  
Central TB Laboratory  
Ministry of Health  
PO Box 20781  
Nairobi

**Mozambique**

Dr Alfredo MacArthur Junior  
Director of NTLCP  
Chief of Communicable Diseases Repartition  
Ministry of Health  
Avenue Eduardo Mondlane No. 1008  
PO Box 264  
Maputo

Mr Salomão Jaime Maugate  
Tuberculosis National Reference Laboratory  
c/o National TB and Leprosy Control Programme  
Ministry of Health  
Esquina Eduardo Mondlane Salvador Allende  
Maputo

**Myanmar**

Dr Tin Maung Cho  
Professor and Head  
Department of Chest Medicine  
Yangon General Hospital  
Yangon

Dr Myo Zaw  
Senior Medical Superintendent/Senior Consultant  
National Tuberculosis Programme  
Yangon General Hospital (Extension Compound)  
Yangon
Nigeria

Dr Sani Nasir Gwarzo
National Programme Manager
Tuberculosis & Leprosy Control Programme
Federal Ministry of Health
Plot 1025 Accra Street
Wuse Zone 2, FCT
Abuja

Mrs Abiola O. Tubi
National Laboratory Technologist
Tuberculosis & Leprosy Control Programme
Federal Ministry of Health
Plot 1025 Accra Street
Wuse Zone 2, FCT
Abuja

Pakistan

Dr Hassan Sadiq
Deputy National Manager
National TB Control Programme
Government TB Centre
Asghar Mall Road
Rawalpindi

Dr Syed Karam Shah
Manager, National TB Control Programme
Ministry of Health, Federal Government
Government TB Centre
Asghar Mall Road
Rawalpindi

Dr Sabira Tahseen
National TB Control Programme
Federal Government TB Centre
Government TB Centre
Asghar Mall Road
Rawalpindi

Peru

Dr Cesar Bonilla
Jr Los Opalos 225 Urbanización Benjamin Doig, La Perla, Callao 4
Lima

Dr Luis Asencio
c/o Representante de la OPS/OMS en el Peru
Oficina Sanitaria Panamericana
Casilla 2117
Lima 100

Philippines

Dr Nora Cruz
Medical Specialist IV
National TB Reference Laboratory
Research Institute for Tropical Medicine
Filinvest Corporate City
Alabang, Muntinlupa City

Dr Jaime Lagahid
Director, Infectious Diseases
National Disease Prevention and Control Office
Department of Health
Sta. Cruz, Manila

Dr Thelma Tupasi
Tropical Disease Foundation, Inc.
Makati Medical Center
No. 2 Amorsolo Street
1200 Makati City

Dr Rosalind Vianzon
National TB Manager
Department of Health
Sta. Cruz, Manila

Russian Federation

Ms Galina Makhakova
Deputy Director
Ministry of Health and Social Development of the Russian Federation
3 Rakhmanovskiy per.
Moscow 101431

Dr Serguei Alexandrovich Popov
Head, Microbiology Laboratory
Research Institute of Phthisiopulmonology
13–59 Yubileyny, Reutov
Moscow 143965

South Africa

Dr Lindiwe Mvusi
Chief Medical Officer
National TB and Leprosy Programme
Department of Health
PO Box X828
0001 Pretoria
Dr Xoliswa Poswa  
Head, National Health Laboratory Services  
Department of Health  
PO Box 1038  
Johannesburg 2000

Dr Le Ngoc Van  
National Hospital of Tuberculosis and Respiratory Disease  
463 Hoang Hoa Tham, Ba Dinh  
Hanoi

Thailand

Dr Sripapa Nateniyom  
Chief of TB Cluster  
Bureau of AIDS, TB and STIs  
Department of Disease Control  
Ministry of Public Health  
Tivanond Road  
Nonthaburi 11000

Ms Regina Bhebe  
Head, National TB Reference Laboratory  
Ministry of Health and Child Welfare  
PO Box CY  
Causeway  
Harare

Mr Somsak Rieengthong  
Senior Medical Scientist, TB Cluster  
Bureau of AIDS, TB and STIs  
Department of Disease Control  
Ministry of Public Health  
Tivanond Road  
Nonthaburi 11000

Dr Milton Chemhuru  
Coordinator STI/AIDS and TB Unit  
Ministry of Health and Child Welfare  
PO Box CY  
Causeway  
Harare

Uganda

Dr Francis Adatu-Engwau  
Programme Manager  
National TB and Leprosy Programme  
Ministry of Health  
PO Box 16069  
Kampala

United Republic of Tanzania

Ms Basra Doulla  
Laboratory Health Scientist  
Central TB Reference Laboratory  
Ministry of Health  
PO Box 9083  
Dar es Salaam

Dr Saidi M. Egwaga  
Programme Manager, National TB/Leprosy Programme, Ministry of Health  
PO Box 9083  
Dar es Salaam

Viet Nam

Dr Dinh Ngoc Sy  
Manager, National TB Programme  
463 Hoang Hoa Tham, Ba Dinh  
Hanoi
Donor agencies

Canada

Mr Fraser Fowler
Programme Manager, Programme Against Hunger, Malnutrition and Disease
Canadian International Development Agency
200 Promenade du Portage
L1A 0G4 Hull
Quebec

Germany

Dr Peter Reff
Senior Health and Population Specialist
Asia and Pacific
Kreditanstalt für Wiederaufbau (KFW)
German Development Bank
AS b/1, Palmengartenstr. 5–9
60325 Frankfurt/M

Switzerland

Dr Vinand Nantulya
Director Strategy and Evaluation
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Geneva Secretariat
53, Avenue Louis-Casaï
1216 Geneva-Cointrin

United Kingdom

Dr Billy Stewart
Health Adviser
Global Health Partnerships Team
Policy Division
Department for International Development
1, Palace Street
London SW1E 5HE

United States of America

Dr Olusoji Adeyi
Coordinator of Communicable Disease Partnerships
Health, Nutrition and Population
The World Bank
1818 H. Street NW
Washington, DC 20433

Ms Susan Bacheller
TB Team Leader
Office of Health, Infectious Diseases & Nutrition
United States Agency for International Development, 3.06-80, 3rd floor
Ronald Reagan Building
Washington, DC 20523-5900

Dr Amy Bloom
Senior Technical Advisor
Office of HIV/AIDS
Bureau for Global Health
United States Agency for International Development, 5.10.45, 5th Floor
Ronald Reagan Building
Washington, DC 20523-3700

Mr L. Richard Meyers
Senior Operations Officer
Human Development Sector Unit
East Asia & Pacific Region
The World Bank
1818 H. Street N.W.
Washington, DC 20433

Dr Birte Holm Sorensen
Senior Public Health Specialist
SASHD
The World Bank
Room MC 11-838
1818 H St. NW
Washington, DC 20433

Ms Cheri Vincent
Public Health Advisor
Global Health Bureau
Office of Health & Infectious Disease
United States Agency for International Development
Ronald Reagan Building
Washington, DC 20523-3700
Technical agencies/other partners

Belgium

Dr Etienne Declercq
Medical Adviser
Damien Foundation Belgium
263 Bd Léopold II
1081 Brussels

Dr Myriam Henkens
International Medical Coordinator
International Office
Médecins Sans Frontières
Rue de la Tourelle 39
1040 Brussels

Dr Francine Matthys
Directeur médical
Médecins Sans Frontières
Rue Dupré 94
1090 Brussels

Professor Françoise Portaels
Département de Microbiologie
Unité de Mycobactériologie
Institut de Médecine Tropicale
Nationalestraat 155
2000 Antwerpen

Cambodia

Mr Takashi Miura
Adviser for National TB Laboratory
CENAT/JICA National TB Control Project
c/o JICA Cambodia Office
PO Box 613
Phnom Penh

Dr Kosuke Okada
Chief Adviser
CENAT/JICA National TB Control Project
c/o JICA Cambodia Office
PO Box 613
Phnom Penh

France

Dr Paula Fujiwara
Deputy Executive Director
International Union Against Tuberculosis &
Lung Disease
68 boulevard Saint-Michel
75006 Paris

Ms Aurelie Gloaguen
Association Nationale des Etudiants en
Médecine de France
c/o FAGE
5, Rue Fréderick Lemaitre
75020 Paris

Dr Arnaud Trébucq
Head of Tuberculosis Division
International Union Against Tuberculosis &
Lung Disease
68 boulevard Saint-Michel
75006 Paris

Dr Francis Varaine
Médecins Sans Frontières - France
8 rue St Sabin
75544 Paris Cedex 11

Germany

Dr Assia Brandrup-Lukanow
Director
Department of Health, Education and Social
Protection
German Agency for Technical Cooperation
Dag-Hammarskjöld-Weg 1–5
Postfach 5180
63726 Eschborn

Dr Thomas von Stamm
Medical Adviser
German Leprosy and TB Relief Association
Mariannhillstr. 1c
97074 Wuerzburg

Iceland

Dr Thorstein Blondal
Chief Physician for TB
Council of the Baltic Sea States
Baronsstigur 47
101 Reykjavik

Dr Kai Vink
KNCV Tuberculosis Foundation
Hjardarhag 48
107 Reykjavik
Italy

Dr Lanfranco Fattorini
Laboratory of Bacteriology and Medical Mycology
Instituto Superiore di Sanità
Viale Regina Elena 299
00161 Rome

Dr Giovanni Battista Migliori
Director, WHO Collaborating Centre for Tuberculosis and Lung Diseases
Fondazione Salvatore Maugeri, IRCCS
Via Roncaccio 16
21049 Tradate, VA

Japan

Dr Nobukatsu Ishikawa
The Research Institute of TB
Japan Anti-Tuberculosis Association
3-1-24 Matsuyama, Kiyose
Tokyo 204 0022

Dr Ikusi Onozaki
Chiba Foundation for Health Promotion and Disease Prevention (Chiba Anti-TB Association)
1-1-20 Miyakocho, Chuou-ku
Chiba 260-0001

Myanmar

Dr Guy Stallworthy
Myanmar Country Director
Population Services International
15-C, Aung Min Gaung Street
PO Box 752
Kamayut, Yangon

Netherlands

Dr Jaap Broekmans
General Director
KNCV Tuberculosis Association
PO Box 146
2501 CC The Hague

Dr Peter Gondrie
Coordinator, International Programme Support Unit
KNCV Tuberculosis Association
PO Box 146
2501 CC The Hague

Ms Sara Massaut
Senior Staff Officer PMU-TBCTA
KNCV Tuberculosis Foundation
PO Box 146
2501 CC The Hague

Mrs Gerdy Schippers
Director of Finance and Organisation
KNCV Tuberculosis Association
PO Box 146
2501 CC The Hague

Dr Maarten van Cleeff
Project Director TBCTA
KNCV Tuberculosis Association
PO Box 146
2501 CC The Hague

Norway

Dr Einar Heldal
Senior Medical Officer
Division of Infectious Disease Control
Norwegian Institute of Public Health
Geitmysveien 75
PO Box 4404 Nydalen
0403 Oslo

Mrs Mette Klouman
Manager, International Cooperation Development Aid Department
Norwegian Heart and Lung Patient Organisation
Sandakerveien 99, PB 4375, Nydalen
0402 Oslo-4

Pakistan

Dr Hiroto Miyagi
Chief Technical Advisor to NTP
JICA Office
F.G. Tuberculosis Center
Asghar Mall Road
Rawalpindi

Dr Wajiha Qureshi
Medical Officer, NTP
F.G. Tuberculosis Center
Asghar Mall Road
Rawalpindi
Philippines

Ms Dorotea Bacalso
JICA Philippine Office
12th Floor Pacific Star Building
Sen. Gil Puyat Ave. cor. Makati Avenue
Makati City

Dr Cristina Giango
JICA Philippine Office
12th Floor Pacific Star Building
Sen. Gil Puyat Ave. cor. Makati Avenue
Makati City

Dr Arthur Lagos
JICA Philippine Office
12th Floor Pacific Star Building
Sen. Gil Puyat Ave. cor. Makati Avenue
Makati City

Republic of Korea

Dr Sang Jae Kim
Laboratory Consultant
International Union Against Tuberculosis & Lung Disease
101–703 Unejeongmaeul, 621 Mabukri
Guseongup, Yonginsi
449-912 Kyeonggido

South Africa

Dr Robert Gie
Head, Department of Paediatrics & Child Health
University of Stellenbosch
Faculty of Medicine
PO Box 19063
7505 Tygerberg

Switzerland

Dr Christian Auer
Public Health Researcher
Swiss Tropical Institute
Socinstrasse 57
4002 Basel

Ms Francesca Boldrini
Project Manager
World Economic Forum
Global Health Initiative
91–93 Route de la Capite
1223 Cologny, Geneva

Dr Gerard Brise
Chief Medical Officer
International Committee of the Red Cross
19 Avenue de la Paix
1202 Geneva

Dr Patrizia Carlevaro
Head of International Aid Unit
Eli Lilly Export S.A.
PO Box 580
16 chemin des Coquelicots
1214 Vernier

Dr Lasha Goguadze
Senior Health Officer, Europe Region
Health and Care Department
International Federation of Red Cross/Red Crescent Societies
17 chemin des Crêts
Petit-Saconnex
1211 Geneva 19

Ms Laura Hakokongas
Director of Communications
Campaign for Access to Essential Medicines
Médecins Sans Frontières
78 rue de Lausanne
Postfach 116
1211 Geneva

Dr Giorgio Roscigno
Chief Executive Officer
Foundation for Innovative New Diagnostics
71 Avenue Louis-Casaï
Case postale 93
1216 Cointrin, Geneva

Dr Esther Schelling
Department of Public Health & Epidemiology
Swiss Tropical Institute
Socinstrasse 57, PO Box
4002 Basel

Ms Daryl Somma
Department of Public Health & Epidemiology
Swiss Tropical Institute
Socinstrasse 57, PO Box
4002 Basel
United Kingdom

Dr Paul Sommerfeld
TB Alert
22 Tiverton Road
London NW10 3HL

Dr Bertie Squire
EQUI TB Programme Manager
EQUI TB Knowledge Programme
Liverpool School of Tropical Medicine
Pembroke Place
Liverpool L3 5QA

Ms Gini Williams
Head of Nursing Division
St Bartholomews School of Nursing and Midwifery
International Union Against Tuberculosis & Lung Disease
Alexandra Building
Philipot Street, Whitechapel
London E1 2EA

United States of America

Ms Donna Barry
Russia Program Director
Partners In Health
Harvard Medical School, Program in Infectious Disease and Social Change
641 Huntington Avenue
Boston, MA 02115

Dr Kenneth Castro
Assistant Surgeon General
United States Public Health Service
Director, Division of Tuberculosis Elimination
National Center for HIV, STD, and TB Prevention
Centers for Disease Control and Prevention
1600 Clifton Rd. NE, MS E-10
Corporate Square Boulevard, Bldg 10
Atlanta, GA 30329

Ms Fran Du Melle
Deputy Managing Director
American Lung Association
1726 M Street, NW, Suite 902
Washington, DC 20036

Dr Ann Ginsberg
Head of Clinical Development
Global Alliance for TB Drug Development
80 Broad Street
31st Floor
New York, NY 10004

Ms Rachel Guglielmo
Soros Open Society Institute
FXB Center for Health and Human Rights
Harvard School of Public Health
651 Huntington Ave, 7th floor
Boston, MA 02115

Dr Christy Hanson
Senior Program Officer
PATH
1800 K Street NW, Suite 800
Washington, DC 20006

Mr Mark Harrington
Executive Director
Treatment Action Group
611 Broadway, Suite 612
New York, NY 10012

Dr Philip Hopewell
American Thoracic Society
61 Broadway, 4th Floor
New York, NY 10006

Dr Michael Kimerling
Director, UAB International TB Center
Principal Investigator, UAB Coordinating Site of the Gorgas Tuberculosis Initiative
University of Alabama at Birmingham
RPHB 443, 1530 3rd Ave South
Birmingham, AL 35294-0022

Dr Catherine Mundy
Principal Program Associate for Laboratory Services, TB and HIV Unit
Centre for Health Systems and Services Management Sciences for Health
891 Centre Street
Boston, MA 02130

Dr Robert Northrup
Senior Technical Adviser
Project Hope
255 Carter Hall Lane
Millwood, VA 22646
Dr Lee B. Reichmann  
Executive Director  
New Jersey Medical School  
National Tuberculosis Center  
65 Bergen Street, Suite GB 1  
Newark, NJ 07107-3001

Ms Nina Schwalbe  
Director of Network, Public Health Program  
Soros Open Society Institute  
400 West 59th Street  
New York, NY 10019

Dr Wanda Walton  
Chief, Communications, Education, and Behavioural Studies Branch  
Division of Tuberculosis Elimination  
Centers for Disease Control and Prevention  
1600 Clifton Road NE, Mailstop-E10  
Atlanta, GA 30333

Dr Charles Wells  
Chief, International Research and Programs Branch  
Division of Tuberculosis Elimination  
Centers for Disease Control and Prevention  
1600 Clifton Rd NE  
Mailstop E-10  
Atlanta, GA 30333

Dr Christine Whalen  
Director, TB and TB/HIV Unit  
Centre for Health systems and Services Management Sciences for Health  
891 Centre Street  
Boston, MA 02130

Dr Andrey Zagorskiy  
Project Manager for TB, Europe and Eurasia  
Rational Pharmaceutical Management Plus Program  
Management Sciences for Health  
4301 North Fairfax Drive  
Suite 400  
Arlington, VA 22203-1627
WHO regional/country office staff

Regional Office for Africa (AFRO)
Dr Wilfred Nkhoma
Dr Ayodele Awe (WHO Nigeria)
Dr Bah-Keita (WHO Côte d'Ivoire)
Dr Oumou Bah-Sow
Dr Daniel Kibuga
Dr Robert Makombe
Dr Giampaolo Mezzabotta (WHO Uganda)
Dr Jan van den Hombergh (WHO Ethiopia)
Ms Lisa Véron

Regional Office for the Americas/Pan American Sanitary Bureau (AMRO/PAHO)
Dr Mirtha del Granado
Dr J.C. Millan (WHO Peru)
Dr Pilar Ramon Pardo
Dr Rodolfo Rodriguez-Cruz (WHO Brazil)
Dr Matias Villatoro

Regional Office for South-East Asia (SEARO)
Dr Nani Nair
Dr Marijke Becx-Bleumink (WHO Bangladesh)
Dr Christian Gunneberg (WHO Nepal)
Dr Hans Kluge (WHO Myanmar)
Dr Davide Manissero (WHO Indonesia)
Dr Suwanand Sahu (WHO India)
Dr Douglas Fraser Wares (WHO India)

Regional Office for Europe (EURO)
Dr Richard Zaleskis
Dr Wieslaw Jakubowiak (WHO Russian Federation)
Dr Kestutis Miskinis (WHO Ukraine)
Mr Jerod Scholten
Dr Yelena Yurasova

Regional Office for the Eastern Mediterranean (EMRO)
Dr Samiha Baghdadi
Dr Sevil Hosseinova (WHO Afghanistan)

Regional Office for the Western Pacific (WPRO)
Dr Dong Il Ahn
Dr Maarten Bosman (WHO Viet Nam)
Dr Daniel Chin (WHO China)
Dr Philippe Glaziou
Dr Michael Vonlatis (WHO Philippines)
Dr Lixia Wang (WHO China)

WHO headquarters staff

Stop TB Department (STB)
Dr Mario Raviglione
Mr Glenn Thomas
Ms Diana Weil

TB Strategy and Operations (TBS)
Dr Léopold Blanc
Dr Mohamed Aziz
Ms Karin Bergstrom
Dr José Figueroa-Muñoz
Dr Giuliano Gargioni
Dr Malgorzata Grzemska
Dr Adalbert Laszlo
Dr Knut Lönnroth
Dr Salah-Eddine Ottmani
Ms Amy Piatek
Ms Krystyna Ryszewska
Dr Holger Sawert
Ms Joanne Sheppard
Dr Mukund Uplekar
Ms Lana Velebit
Ms Amina L’Kima (secretariat)
Mrs Dorris Ortega (secretariat)

Tuberculosis Monitoring and Evaluation (TME)
Dr Christopher Dye
Dr Daniel Bleed
Dr Katherine Floyd
Dr Mehran Hosseini
Dr Catherine Watt
Dr Brian Williams

TB/HIV and Drug Resistance (THD)
Dr Paul Nunn
Dr Haileyesus Getahun
Dr Ernesto Jaramillo
Dr Kitty Lambregts
Dr Alasdair Reid
Dr Fabio Scano

Stop TB Partnership Secretariat (TBP)
Ms Valerie Diaz
Mr Peter Evans
Ms Petra Heitkamp
Dr Dermot Maher
Mr Satyajit Sarker

Evidence and Information for Policy, Health Systems Policies and Operations (EIP/SPO)
Dr Phyllida Travis